AntiCancer, Inc., San Diego, CA, U.S.A.
Anticancer Res. 2021 Apr;41(4):1921-1926. doi: 10.21873/anticanres.14958.
BACKGROUND/AIM: Methionine addiction is a general and fundamental hallmark of cancer due to the excess use of methionine for transmethylation reactions, termed the "Hoffman Effect". Methionine addiction has been shown to be a highly-effective target for cancer therapy by methionine restriction with oral recombinant methioninase (o-rMETase) in preclinical studies, including patient- derived orthotopic xenograft (PDOX) mouse models of cancer. A clinical study of o-rMETase as a supplement showed a 70% reduction of PSA levels in a patient with bone-metastatic prostate cancer.
In the present study, two advanced prostate-cancer patients took o-rMETase as a supplement for approximately one month.
One of the patients taking o-rMETase showed a 38% reduction of PSA levels and the second patient showed a 20% PSA reduction.
o-rMETase shows promise for treating patients with advanced prostate cancer.
背景/目的：由于用于转甲基反应的蛋氨酸过量，蛋氨酸成瘾是癌症的一个普遍和基本特征，这被称为“霍夫曼效应”。临床前研究表明，通过蛋氨酸限制和口服重组蛋氨酸酶（o-rMETase）治疗可以有效地针对癌症，包括患者来源的原位异种移植（PDOX）癌症小鼠模型。o-rMETase 作为补充剂的临床研究显示，骨转移前列腺癌患者的 PSA 水平降低了 70%。
本研究中，两名晚期前列腺癌患者服用 o-rMETase 作为补充剂约一个月。
其中一名接受 o-rMETase 治疗的患者 PSA 水平降低了 38%，第二名患者 PSA 降低了 20%。
o-rMETase 有望治疗晚期前列腺癌患者。
